Paliperidone-Cation Exchange Resin Complexes of Different Particle Sizes for Controlled Release.

Jun-Pil Jee, Young Hoon Kim, Jun Hak Lee, Kyoung Ah Min, Dong-Jin Jang, Sung Giu Jin, Kwan Hyung Cho
Author Information
  1. Jun-Pil Jee: College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea.
  2. Young Hoon Kim: College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Republic of Korea.
  3. Jun Hak Lee: College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Republic of Korea.
  4. Kyoung Ah Min: College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Republic of Korea.
  5. Dong-Jin Jang: Department of Bio-Health Technology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea.
  6. Sung Giu Jin: Department of Pharmaceutical Engineering, Dankook University, Cheonan 31116, Republic of Korea. ORCID
  7. Kwan Hyung Cho: College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Republic of Korea.

Abstract

This study aimed to develop electrolyte complexes of paliperidone (PPD) with various particle sizes using cation-exchange resins (CERs) to enable controlled release (both immediate and sustained release). CERs of specific particle size ranges were obtained by sieving commercial products. PPD-CER complexes (PCCs) were prepared in an acidic solution of pH 1.2 and demonstrated a high binding efficiency (>99.0%). PCCs were prepared with CERs of various particle sizes (on average, 100, 150, and 400 μm) at the weight ratio of PPD to CER (1:2 and 1:4). Physicochemical characterization studies such as Fourier-transform infrared spectroscopy, differential scanning calorimetry, powder X-ray diffraction, and scanning electron microscopy between PCCs (1:4) and physical mixtures confirmed PCC formation. In the drug release test, PPD alone experienced a complete drug release from PCC of >85% within 60 min and 120 min in pH 1.2 and pH 6.8 buffer solutions, respectively. Alternatively, PCC (1:4) prepared with CER (150 μm) formed spherical particles and showed an almost negligible release of PPD in pH 1.2 buffer (<10%, 2 h) while controlling the release in pH 6.8 buffer (>75%, 24 h). The release rate of PPD from PCCs was reduced with the increase in CER particle size and CER ratio. The PCCs explored in this study could be a promising technology for controlling the release of PPD in a variety of methods.

Keywords

References

  1. Pharmaceutics. 2022 Sep 05;14(9): [PMID: 36145623]
  2. Drug Deliv. 2022 Dec;29(1):1409-1422 [PMID: 35532148]
  3. Pharmaceutics. 2022 Aug 14;14(8): [PMID: 36015320]
  4. Ther Deliv. 2021 Aug;12(8):583-596 [PMID: 34286598]
  5. Int J Nanomedicine. 2021 Aug 24;16:5797-5810 [PMID: 34465992]
  6. Chem Asian J. 2022 Nov 2;17(21):e202200595 [PMID: 36066570]
  7. Drug Deliv. 2017 Nov;24(1):370-379 [PMID: 28165833]
  8. Pharmaceutics. 2019 Aug 16;11(8): [PMID: 31426411]
  9. Carbohydr Polym. 2017 Dec 1;177:49-57 [PMID: 28962795]
  10. Pharm Dev Technol. 2021 Jun;26(5):522-538 [PMID: 33663316]
  11. Int J Mol Sci. 2020 Oct 23;21(21): [PMID: 33114195]
  12. Int J Pharm. 2013 Oct 15;455(1-2):31-9 [PMID: 23933050]
  13. Carbohydr Polym. 2021 Nov 1;271:118433 [PMID: 34364573]
  14. Chemosphere. 2020 Jul;251:126331 [PMID: 32145572]
  15. AAPS PharmSciTech. 2018 Feb;19(2):719-729 [PMID: 28971358]
  16. Int J Pharm. 2021 Mar 15;597:120377 [PMID: 33581270]
  17. Int J Pharm. 2015 Jul 25;490(1-2):273-80 [PMID: 26024820]
  18. J Control Release. 2016 May 28;230:95-108 [PMID: 27067365]
  19. AAPS PharmSciTech. 2022 Apr 5;23(4):105 [PMID: 35381945]
  20. Expert Rev Neurother. 2012 Dec;12(12):1399-410 [PMID: 23237347]
  21. Pharmaceutics. 2020 Feb 16;12(2): [PMID: 32079093]
  22. Chem Phys Lipids. 2021 Jan;234:105005 [PMID: 33144070]
  23. Healthcare (Basel). 2022 Mar 07;10(3): [PMID: 35326970]
  24. Int J Pharm. 2022 Nov 25;628:122286 [PMID: 36252642]
  25. Int J Pharm. 2018 Jul 10;545(1-2):163-169 [PMID: 29729403]
  26. Pharmaceutics. 2018 Nov 28;10(4): [PMID: 30487449]
  27. Polymers (Basel). 2021 Dec 15;13(24): [PMID: 34960946]
  28. Psychosomatics. 2010 Jan-Feb;51(1):80-8 [PMID: 20118446]
  29. ACS Chem Neurosci. 2018 Jul 18;9(7):1520-1529 [PMID: 29695153]
  30. J Nanosci Nanotechnol. 2021 Jul 1;21(7):3679-3682 [PMID: 33715673]
  31. J Nanosci Nanotechnol. 2020 Sep 1;20(9):5796-5799 [PMID: 32331183]
  32. Neuropsychiatr Dis Treat. 2021 Oct 19;17:3159-3170 [PMID: 34703236]

Grants

  1. NRF-2022R1A2C1003070/National Research Foundation of Korea

Word Cloud

Created with Highcharts 10.0.0releasePPDparticlePCCspH2CERCERssizeprepared11:4PCCbufferstudycomplexespaliperidonevarioussizescontrolled150μmratioscanningdrugmin68hcontrollingresinaimeddevelopelectrolyteusingcation-exchangeresinsenableimmediatesustainedspecificrangesobtainedsievingcommercialproductsPPD-CERacidicsolutiondemonstratedhighbindingefficiency>990%average100400weight1:2PhysicochemicalcharacterizationstudiesFourier-transforminfraredspectroscopydifferentialcalorimetrypowderX-raydiffractionelectronmicroscopyphysicalmixturesconfirmedformationtestaloneexperiencedcomplete>85%within60120solutionsrespectivelyAlternativelyformedsphericalparticlesshowedalmostnegligible<10%>75%24ratereducedincreaseexploredpromisingtechnologyvarietymethodsPaliperidone-CationExchangeResinComplexesDifferentParticleSizesControlledReleasecationexchange

Similar Articles

Cited By